Patent: 9,345,770
✉ Email this page to a colleague
Summary for Patent: 9,345,770
| Title: | Immunogenic tumor associated stromal cell antigen peptides and methods of their use |
| Abstract: | Immunogenic peptides from tumor associated stromal cell antigens, including combinations of such peptides, are disclosed herein. In some examples the peptides are useful for methods of eliciting an immune response. In additional examples the peptides are useful for methods of treating cancer. Methods for decreasing vascularization of a tumor using a Protein Delta Homolog 1 (DLK1) protein or a nucleic acid encoding the protein are also disclosed. |
| Inventor(s): | Storkus; Walter J. (Pittsburgh, PA), Bose; Anamika (Kolkata, IN), Taylor; Jennifer Lynn (McDonald, PA), Zhao; Xi (Pittsburgh, PA), Lowe; Devin B. (Pittsburgh, PA) |
| Assignee: | University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA) |
| Application Number: | 14/358,705 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,345,770
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2031-11-16 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
